|Articles|August 29, 2019
High-touch services that enhance patient outcomes
Author(s)McKesson Life Sciences
In today’s evolving, value-based environment for specialty drugs, high-touch services that enhance patient outcomes are playing an increasingly important role in market access and patient care delivery. Using gene therapy as a specific example, this white paper will discuss many of the high-touch services that can help enhance patient outcomes.
Related Content
Trending on PharmExec
1
AstraZeneca Shares Drop Following Wainua’s Failed Heart Disease Trial
2
U.S. Supreme Court Weighs Inducement Liability Beyond FDA Carve-Out Labels
3
Pharma M&A Roundup: Chemomab Therapeutics Enters Merger Agreement with Scipher Medicine, Teva and Polpharma Biologics Enter Global Licensing Agreement
4
FDA Approves Subcutaneous Sarclisa Escena for Multiple Myeloma
5